دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Assessment of Toxic Effects and Survival in Treatment Deescalation With Radiotherapy vs Transoral Surgery for HPV-Associated Oropharyngeal Squamous Cell CarcinomaThe ORATOR2 Phase 2 Randomized Clinical Trial
David A. Palma, MD, PhD; Eitan Prisman, MD; Eric Berthelet, MD; et al.
doi : 10.1001/jamaoncol.2022.0615
June 2022, Vol 8, No. 6, Pages 1-951
Quality-of-Life Outcomes and Toxic Effects Among Patients With Cancers of the Uterus Treated With Stereotactic Pelvic Adjuvant Radiation TherapyThe SPARTACUS Phase 1/2 Nonrandomized Controlled Trial
Eric Leung, MD, MSc; Adam P. Gladwish, MD, MSc; Melanie Davidson, PhD; et al.
Association of Pathogenic Variants in Hereditary Cancer Genes With Multiple Diseases
Chenjie Zeng, PhD, MPH; Lisa A. Bastarache, MS; Ran Tao, PhD; et al.
Association of Medicaid Expansion With Mortality Disparity by Race and Ethnicity Among Patients With De Novo Stage IV Breast Cancer
Catalina Malinowski, MPH, CHES, CHW; Xiudong Lei, PhD; Hui Zhao, PhD; et al.
Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants
Yukihide Momozawa, PhD; Rumi Sasai, MA; Yoshiaki Usui, MD; et al.
Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug Class
Joseph N. Samuel, PharmD, MSc; Christopher M. Booth, MD; Elizabeth Eisenhauer, MD; et al.
Identifying Patients Whose Symptoms Are Underrecognized During Treatment With Breast Radiotherapy
Reshma Jagsi, MD, DPhil; Kent A. Griffith, MS, MPH; Frank Vicini, MD; et al.
Racial and Ethnic Differences in Hysterectomy-Corrected Uterine Corpus Cancer Mortality by Stage and Histologic Subtype
Megan A. Clarke, PhD, MHS; Susan S. Devesa, PhD, MHS; Anne Hammer, MD, PhD; et al.
Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine TumorsA Nonrandomized Clinical Trial
Daniel M. Halperin, MD; Suyu Liu, PhD; Arvind Dasari, MD; et al.
Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell CarcinomaResults of the BONSAI Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study)
Giuseppe Procopio, MD; Pierangela Sepe, MD; Melanie Claps, MD; et al.
Association of the COVID-19 Pandemic With Rates of Prostate Cancer Biopsies and Diagnoses in Black vs White US Veterans
Zachary Klaassen, MD, MSc; Shannon Stock, PhD; Justin Waller, MS; et al.
Ipilimumab/Nivolumab Therapy in Patients With Metastatic Pancreatic or Biliary Cancer With Homologous Recombination Deficiency Pathogenic Germline Variants
Gretel Terrero, MD; Jashodeep Datta, MD; Jessica Dennison, BA; et al.
Long-term Immunogenicity of BNT162b2 Vaccine in Patients With Solid Tumors
Ithai Waldhorn, MD; Roy Holland, MD; Tal Goshen-Lago, PhD; et al.
Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB)A Systematic Review and Delphi Consensus Statement
Esther N. Pijnappel, MD; J. Annelie Suurmeijer, MD; Bas Groot Koerkamp, MD, PhD; et al.
Addressing Sex Disparities in Academic OncologyWhat Can We Do?
Kristina Jenei, BSN, MSc; Malinda T. West, MD, MS; Myung S. Kim, MD
Enabling the Sharing of Single-Dose Vials Through Risk Mitigation to Decrease Financial Toxicity
Daniel A. Goldstein, MD; R. Donald Harvey, PharmD; Kelvin K. W. Chan, MD, PhD
Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma—Challenges and Potential Solutions
Samer Al Hadidi, MD, MS; Maurizio Zangari, MD; Frits van Rhee, MD, PhD
A Phenome-Wide Association Study and the Discovery of a New Clinical Spectrum of Hereditary Cancer Genes
Kailin Yang, MD, PhD; Jacob G. Scott, MD, DPhil
The ORATOR Trials Have Spoken—Where Do We Go From Here?
Sewit Teckie, MD; Neil D. Gross, MD
Are We Finally Ready for the Widespread Adoption of Stereotactic Radiation in Gynecologic Cancers?
Vonetta M. Williams, MD, PhD; Onyinye Balogun, MD, MSc; Kaled Alektiar, MD
A Decision Shared Is a Decision Halved
Edward R. Scheffer Cliff, MBBS(Hons), BMedSc(Hons)
Is Regional Nodal Radiotherapy Necessary for Patients With cN1 and ypN0 Breast Cancer After Neoadjuvant Chemotherapy?
Yanhong Wang, MM; Yi Ouyang, MD; Qunrong Cai, MM
Is Regional Nodal Radiotherapy Necessary for Patients With cN1 and ypN0 Breast Cancer After Neoadjuvant Chemotherapy?—Reply
Andrea V. Barrio, MD; Giacomo Montagna, MD, MPH; Monica Morrow, MD
Clinical Utility Assessment of Gonadotropin-Releasing Hormone Analogs Among Women Younger Than 35 Years
Zachary R. McCaw, PhD; Lee-Jen Wei, PhD
Clinical Utility Assessment of Gonadotropin-Releasing Hormone Analogs Among Women Younger Than 35 Years—Reply
Yang Yu, MD; Xiangyun Zong, MD, PhD
Concerns Remain Regarding the Association of Sitting Time and Physical Activity With Cancer Survivorship
Yicheng Zhang, MD; Jin Zhang, MD; Peiming Sun, MD, PhD
Concerns Remain Regarding the Association of Sitting Time and Physical Activity With Cancer Survivorship
Taichiro Goto, MD, PhD
Concerns Remain Regarding the Association of Sitting Time and Physical Activity With Cancer Survivorship—Reply
Chao Cao, MPH; Christine M. Friedenreich, PhD; Lin Yang, PhD
Evidence Base on the Potential Carcinogenicity of Radiofrequency Radiation
Olga V. Naidenko, PhD
Evidence Base on the Potential Carcinogenicity of Radiofrequency Radiation
David O. Carpenter, MD; Lennart Hardell, MD, PhD; Cindy Sage, MA
Evidence Base on the Potential Carcinogenicity of Radiofrequency Radiation
Najmeh Jooyan, PhD; Seyed Mohammadjavad Mortazavi, PhD
Evidence Base on the Potential Carcinogenicity of Radiofrequency Radiation—Reply
David Robert Grimes, PhD
